111 related articles for article (PubMed ID: 28196364)
1. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
Camacho X; Machado CL; García MF; Gambini JP; Banchero A; Fernández M; Oddone N; Bertolini Zanatta D; Rosal C; Buchpiguel CA; Chammas R; Riva E; Cabral P
Oncology; 2017; 92(4):229-242. PubMed ID: 28196364
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
[TBL] [Abstract][Full Text] [Related]
3. Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.
Lin X; Zhu H; Luo Z; Hong Y; Zhang H; Liu X; Ding H; Tian H; Yang Z
Mol Imaging Biol; 2014 Dec; 16(6):877-87. PubMed ID: 24833041
[TBL] [Abstract][Full Text] [Related]
4. 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents.
Camacho X; Perroni C; Machado CL; de Godoi Carneiro C; de Souza Junqueira M; Faria D; García MF; Fernández M; Oddone N; Benech J; Buchpiguel CA; Cerecetto H; Chammas R; Riva E; Cabral P; Gambini JP
Anticancer Agents Med Chem; 2021; 21(14):1883-1893. PubMed ID: 33397271
[TBL] [Abstract][Full Text] [Related]
5. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
6. Radiolabelling rituximab with (99m)Tc in three steps procedure.
Fontan C; Bezombes C; Salabert AS; Costes J; Lopez R; Fournie JJ; Avet-Loiseau H; Coulais Y; Payoux P; Tafani M
J Labelled Comp Radiopharm; 2015 Jun; 58(7):274-80. PubMed ID: 26017396
[TBL] [Abstract][Full Text] [Related]
7. Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan A; Arksey N; Iagaru A; Chin FT; Gambhir SS
Mol Imaging; 2015; 14():. PubMed ID: 25762106
[TBL] [Abstract][Full Text] [Related]
8. Preparation and preliminary bioevaluation studies of
Suman SK; Kameswaran M; Pandey U; Sarma HD; Dash A
J Labelled Comp Radiopharm; 2019 Oct; 62(12):850-859. PubMed ID: 31461549
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma.
Camacho X; Machado CL; García MF; Fernández M; Oddone N; Benech J; Gambini JP; Cerecetto H; Chammas R; Cabral P; Riva E
Anticancer Agents Med Chem; 2017; 17(9):1267-1277. PubMed ID: 28270081
[TBL] [Abstract][Full Text] [Related]
10. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma.
Natarajan A; Hackel BJ; Gambhir SS
Clin Cancer Res; 2013 Dec; 19(24):6820-9. PubMed ID: 24097872
[TBL] [Abstract][Full Text] [Related]
11. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
Pandey U; Kameswaran M; Dev Sarma H; Samuel G
Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
13. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
14. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
[TBL] [Abstract][Full Text] [Related]
16. Preparation of clinical-scale
Guleria M; Das T; Kumar C; Amirdhanayagam J; Sarma HD; Banerjee S
J Labelled Comp Radiopharm; 2017 May; 60(5):234-241. PubMed ID: 28181275
[TBL] [Abstract][Full Text] [Related]
17. Investigations of (99m)Tc-labeled glucarate as a SPECT radiotracer for non-small cell lung cancer (NSCLC) and potential tumor uptake mechanism.
Meng L; Xiu Y; Li Y; Xu X; Li S; Li X; Pak KY; Shi H; Cheng D
Nucl Med Biol; 2015 Jul; 42(7):608-13. PubMed ID: 25890861
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
[TBL] [Abstract][Full Text] [Related]
19. Characterization of TCP-1 probes for molecular imaging of colon cancer.
Liu Z; Gray BD; Barber C; Bernas M; Cai M; Furenlid LR; Rouse A; Patel C; Banerjee B; Liang R; Gmitro AF; Witte MH; Pak KY; Woolfenden JM
J Control Release; 2016 Oct; 239():223-30. PubMed ID: 27574992
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.
Natarajan A; Gowrishankar G; Nielsen CH; Wang S; Iagaru A; Goris ML; Gambhir SS
Mol Imaging Biol; 2012 Oct; 14(5):608-16. PubMed ID: 22231277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
